Navigation Links
Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
Date:5/30/2012

LOS ANGELES, May 30, 2012 /PRNewswire/ -- Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS™) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.  The trial is being conducted at UCLA and is funded by NeuroSigma.  Mean decreases in PTSD measures of 36% and depression measures of over 50% were reported.

The study was conducted over an 8-week period and followed similarly designed eTNS trials conducted at UCLA, in which promising results were generated in treating both major depression and epilepsy.  Subjects had a mean age of 54 with a median of 28 years since traumatic exposure and suffered from both PTSD and MDD.  Current episodes were required to be of at least four months in duration, with non-response to at least one antidepressant.  In this outpatient trial, subjects placed stimulating eTNS electrodes on their foreheads for approximately eight hours each night while asleep, and the severity of PTSD and depression symptoms was measured every two weeks using standard recognized rating scales. 

"These findings are very encouraging," said Dr. Cook.  "The combination of depression and an anxiety disorder, like PTSD, is usually difficult to treat effectively.  The participants in the study told us that eTNS was easy to use at home and led, in some instances, to the best mental health they had experienced in years.  We expect these results, along with results from the remaining subjects in this Phase I trial, to form the basis for an upcoming Phase II clinical trial that will examine efficacy, tolerability, and safety in a larger sample with a double-blind, controlled trial design." 

Lodwrick Cook, Chairman of NeuroSigma, added, "PTSD is a serious global disorder drastically in need of promising new therapies.  As Americans we have an obligation to do our utmost to help the thousands of fellow citizens who are stricken by PTSD as a result of both military and non-military related traumatic events.  We are very pleased by the preliminary results and applaud the efforts of the clinical team at UCLA."

PTSD, commonly associated with the effects of warfare, arises after exposure to a traumatic event; such as train bombings and terrorist attacks as experienced on September 11th, or natural disasters such as Hurricane Katrina and the massive Fukushima earthquake and tsunami in Japan, or personal tragedies affecting those involved in traffic accidents, domestic violence or sexual assault.  It is marked by symptoms in three groups: those of re-experiencing (nightmares, flashbacks), those of avoidance and numbing (isolation from others, avoiding reminders), and increased arousal (being on edge, hyper-alert, subject to explosive responses when startled).  PTSD is often accompanied by depression, and many of the medications used to treat PTSD were first developed as antidepressants.  However, recent studies suggest that having an anxiety disorder, such as PTSD, significantly reduces the likelihood that antidepressants will work, making the treatment of PTSD very challenging.  The August 2011 issue of the Journal of the American Medical Association reported that a widely prescribed antipsychotic medication may be no more effective than placebo in treating PTSD.

NeuroSigma, Inc., a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, is the exclusive worldwide licensee of UCLA's TNS intellectual property, including eTNS for PTSD and depression.  Dr. Ian Cook added, "I'm confident that the transfer of the technology from academia to the next phase of trials will go smoothly and that, with replication, this treatment has the opportunity to be made available to help many of those who suffer with PTSD and major depression.  Given the external, non-invasive nature of this therapy, it might be useful in the battlefield or in an emergency room immediately after a traumatic event, with the theoretical potential to impact the development of full-blown PTSD."

Background - TNS
NeuroSigma is commercializing two embodiments of trigeminal nerve stimulation (TNS): eTNS™ (external electrodes and an external pulse generator) and sTNS™ (subcutaneous electrodes and implantable pulse generator).  The eTNS system utilizes a self-adhesive conductive pad applied to the forehead to stimulate branches of the trigeminal nerve, which are located very close to the surface of the skin in the forehead.  The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain.  In clinical studies, eTNS is well tolerated and the low-energy stimulus is confined to the soft tissues of the face without direct penetration into the brain – hence the term "USB Port to the Brain™."

The trigeminal nerve projects to specific areas of the brain, such as the locus coeruleus, nucleus tractus solitarius, thalamus and the cerebral cortex, which are involved in epilepsy, depression, PTSD and other disorders.  PET imaging studies in humans confirms that eTNS activates or inhibits key regions implicated in these disorders and the changes were observed within minutes of therapy.  Once approved by regulatory agencies, patients who respond well to eTNS can opt to switch to the implantable sTNS system.  NeuroSigma has completed development of its eTNS system and is seeking CE Mark approval in Europe for the treatment of epilepsy and depression.  NeuroSigma is concurrently developing its implantable sTNS system.

CAUTION: Both eTNS™ and sTNS™ systems are investigational devices and at this time are limited by Federal (United States) law to investigational use.

About NeuroSigma, Inc.
NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice.  Currently, NeuroSigma is focused on a number of neuromodulation therapies and through its majority-owned subsidiary, NSVascular, Inc., on Thin-Film Nitinol covered stents for endovascular applications.  NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD) via TNS, and for PTSD and obesity via DBS.  For more information about NeuroSigma, please visit http://www.neurosigma.com.

Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements, including but not limited to, research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding our eTNS™ and sTNS™ systems.  These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new medical device products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations.


'/>"/>
SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
2. Codexis Appoints Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
5. Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
6. Golden Meditech FY2011-12 Interim Results
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
9. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
10. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
11. Landauer Elects Board Member Michael T. Leatherman as Interim Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):